Working…
Help guide our efforts to modernize ClinicalTrials.gov.
Send us your comments by March 14, 2020.
ClinicalTrials.gov
ClinicalTrials.gov Menu

Disease Control and Safety in Patients With Relapsing Remitting Multiple Sclerosis (RRMS) Switching From Natalizumab to Fingolimod (TOFIINGO)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT01499667
Recruitment Status : Terminated (Based on recent publications, determination of natalizumub washout period was no longer relevant.)
First Posted : December 26, 2011
Results First Posted : April 4, 2014
Last Update Posted : August 8, 2014
Sponsor:
Information provided by (Responsible Party):
Novartis ( Novartis Pharmaceuticals )

Brief Summary:
This study evaluated disease control during different lengths of treatment transition from natalizumab to fingolimod.

Condition or disease Intervention/treatment Phase
Relapsing Remitting Multiple Sclerosis (RRMS) Drug: Fingolimod Drug: Placebo Phase 3

Detailed Description:

Patient were screened, signed an informed consent at visit 1, at the 2nd visit, all patient received a baseline infusion of Natalizumub and subsequently randomized to one of 3 treatment arms. At the randomization visit, the Washout Phase started, and eligible patients were randomized 1:1:1 to one of three treatment groups:

  • 8-week washout (8 weeks no treatment) followed by 24 weeks of treatment with fingolimod,
  • 12-week washout (8 weeks no treatment and 4 weeks placebo) followed by 20 weeks of treatment with fingolimod, or
  • 16-week washout (8 weeks no treatment and 8 weeks placebo) followed by 16 weeks of treatment with fingolimod.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 142 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double (Participant, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: A 32-week, Patient- and Rater-blinded, Randomized, Multi-center, Parallel-group Study to Evaluate Disease Control and Safety in Patients With Relapsing Remitting Multiple Sclerosis Transferred From Previous Treatment With Natalizumab to Fingolimod (FTY720)
Study Start Date : September 2011
Actual Primary Completion Date : November 2012
Actual Study Completion Date : November 2012

Resource links provided by the National Library of Medicine


Arm Intervention/treatment
Experimental: 8-week washout + Fingolimod (FTY720)
8-week washout (8 weeks no treatment) followed by 24 weeks of treatment with fingolimod 0.5mg once a day
Drug: Fingolimod
Fingolimod 0.5 mg capsules for oral administration once daily

Experimental: 12-week washout + Fingolimod (FTY720)
12-week washout (8 weeks no treatment and 4 weeks placebo) followed by 20 weeks of treatment with fingolimod 0.5mg once a day
Drug: Fingolimod
Fingolimod 0.5 mg capsules for oral administration once daily

Drug: Placebo
Matching placebo in capsules for oral administration once daily.

Experimental: 16-week washout + Fingolimod (FTY720)
16-week washout (8 weeks no treatment and 8 weeks placebo) followed by 16 weeks of treatment with fingolimod 0.5mg once a day
Drug: Fingolimod
Fingolimod 0.5 mg capsules for oral administration once daily

Drug: Placebo
Matching placebo in capsules for oral administration once daily.




Primary Outcome Measures :
  1. Number of Active (New or Newly Enlarging) T2 Lesions From the Last Natalizumab Infusion (Baseline) Through 8 Weeks of Fingolimod Treatment [ Time Frame: Number of active T2 lesions from last natalizumab dose through 8 weeks of fingolimod treatment ]
    Active lesions were measured on brain MRI scans, performed at week 8, compared to the prior scan. The primary variable was analyzed by fitting a negative binomial regression model adjusted for washout group.


Secondary Outcome Measures :
  1. Number of Active (New or Newly Enlarging) T2 Lesions From the Last Natalizumab Infusion (Baseline) up to the Initiation of Fingolimod Treatment [ Time Frame: 8, 12 and 16 weeks (number of active T2 lesions during the washout period only) ]
    Lesions were measured by MRIs and the number of active (new or newly enlarging) T2 lesions was calculated from baseline to beginning of treatment.

  2. Number of Active (New or Newly Enlarging) T2 Lesions During the First 8 Weeks of Fingolimod Treatment [ Time Frame: Number of active T2 lesions during 8 wks of fingolimod treatment ]
    Lesions were measured by MRIs and the number of active (new or newly enlarging) T2 lesions was calculated for first 8 weeks of fingolimod treatment.

  3. Number of Active (New or Newly Enlarging) T2 Lesions During the 24 Weeks After the Last Natalizumab Infusion (Baseline) [ Time Frame: Baseline up to 24 weeks ]
    Lesions will be measured by MRIs and the number of active (new or newly enlarging) T2 lesions will be calculated for 24 weeks from baseline.

  4. Change From Baseline in Expanded Disability Status Scale (EDSS) by Washout Group [ Time Frame: Baseline to week 16 and week 32 ]
    Kurtzke's Expanded Disability Status Scale (EDSS) measures the changes in neurologic impairment, either chronic (progression over time), or acute (MS relapses). The EDSS steps range from 0 (normal) to 10 (death due to MS). Relapse severity is assessed based on severity of neurologic impairment as evaluated using the EDSS.

  5. Cumulative Number of Gadolinium-enhancing T1 Lesions From the Last Natalizumab Infusion [ Time Frame: 8 weeks and 24 weeks ]
    Gadolinium-enhancing lesions will be measured on post-contrast T1-weighted brain MRI scans

  6. Number of Participants With Adverse Events (AE), Serious Adverse Events (SAE) and Death During Washout Period [ Time Frame: Baseline to maximum of 16 weeks ]
    Adverse events were summarized by the number of patients having any adverse event overall.

  7. Number of Participants With Adverse Events (AE), Serious Adverse Events (SAE) and Death During Fingolimod Treatment [ Time Frame: Baseline to maximum of 16 weeks ]
    Adverse events were summarized by the number of patients having any adverse event overall.



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years to 65 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

Patients must:

  • Have relapsing remitting multiple sclerosis
  • Have been on treatment with natalizumab for at least 6 months prior to screening and discontinuation is an option.

Exclusion Criteria:

Patients with:

  • History of chronic immune disease
  • Crohn's disease
  • Certain cancers
  • Uncontrolled diabetes
  • Certain eye disorders
  • Negative for varicella-zoster virus IgG antibodies
  • Certain hepatic conditions
  • Low white blood cell count
  • On certain immunosuppressive medications or heart medications
  • Resting heart rate less than 45 bpm.
  • Certain heart conditions or certain lung conditions
  • Inability to undergo MRI scans

Other protocol-defined inclusion/exclusion criteria may apply


Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01499667


Locations
Layout table for location information
Australia, Victoria
Novartis Investigative Site
Box Hill, Victoria, Australia, 3128
Novartis Investigative Site
Heidelberg, Victoria, Australia, 3084
Austria
Novartis Investigative Site
Vienna, Austria, 1010
Czech Republic
Novartis Investigative Site
Prague 5, Czech Republic, 150 00
Novartis Investigative Site
Praha 2, Czech Republic, 128 08
Novartis Investigative Site
Teplice, Czech Republic, 415 29
Finland
Novartis Investigative Site
Helsinki, Finland, 00100
Germany
Novartis Investigative Site
Ostfildern, Baden-Wuerttemberg, Germany, 73760
Novartis Investigative Site
Bad Mergentheim, Germany, 97980
Novartis Investigative Site
Berlin, Germany, 10713
Novartis Investigative Site
Berlin, Germany, 12163
Novartis Investigative Site
Bielefeld, Germany, 33647
Novartis Investigative Site
Bochum, Germany, 44791
Novartis Investigative Site
Celle, Germany, 29223
Novartis Investigative Site
Erbach, Germany, 64711
Novartis Investigative Site
Erfurt, Germany, 99089
Novartis Investigative Site
Hamburg, Germany, 22083
Novartis Investigative Site
Itzehoe, Germany, 25524
Novartis Investigative Site
Kandel, Germany, 76870
Novartis Investigative Site
Krefeld, Germany, 47805
Novartis Investigative Site
Leipzig, Germany, 04275
Novartis Investigative Site
Münster, Germany, 48149
Novartis Investigative Site
Neuburg, Germany, 86633
Novartis Investigative Site
Neuruppin, Germany, 16816
Novartis Investigative Site
Rüdersdorf, Germany, 15562
Novartis Investigative Site
Siegen, Germany, 57076
Novartis Investigative Site
Ulm, Germany, 89073
Greece
Novartis Investigative Site
Athens, GR, Greece, 115 25
Novartis Investigative Site
Ioannina, GR, Greece, 455 00
Novartis Investigative Site
Thessaloniki, GR, Greece, 570 10
Novartis Investigative Site
Athens, Greece, GR 151 25
Novartis Investigative Site
Athens, Greece, GR-106 76
Hungary
Novartis Investigative Site
Budapest, Hungary, 1074
Novartis Investigative Site
Budapest, Hungary, 1085
Israel
Novartis Investigative Site
Ashkelon, Israel, 78278
Novartis Investigative Site
Jerusalem, Israel, 91120
Italy
Novartis Investigative Site
Milano, MI, Italy, 20132
Novartis Investigative Site
Cefalù, PA, Italy, 90015
Spain
Novartis Investigative Site
Málaga, Andalucia, Spain, 29010
Novartis Investigative Site
Sevilla, Andalucia, Spain, 41009
Novartis Investigative Site
Barcelona, Catalunya, Spain, 08035
Novartis Investigative Site
Barcelona, Spain, 08025
Novartis Investigative Site
Madrid, Spain, 28046
Switzerland
Novartis Investigative Site
Basel, Switzerland, 4031
Sponsors and Collaborators
Novartis Pharmaceuticals
Investigators
Layout table for investigator information
Study Director: Novartis Pharmaceuticals Novartis Pharmaceuticals

Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
Layout table for additonal information
Responsible Party: Novartis Pharmaceuticals
ClinicalTrials.gov Identifier: NCT01499667    
Other Study ID Numbers: CFTY720D2324
2011-001442-15 ( EudraCT Number )
First Posted: December 26, 2011    Key Record Dates
Results First Posted: April 4, 2014
Last Update Posted: August 8, 2014
Last Verified: August 2014
Keywords provided by Novartis ( Novartis Pharmaceuticals ):
Relapsing remitting multiple sclerosis
multiple sclerosis (MS)
safety
tolerability
health outcomes
fingolimod
disease control
MRI
Additional relevant MeSH terms:
Layout table for MeSH terms
Multiple Sclerosis
Multiple Sclerosis, Relapsing-Remitting
Sclerosis
Pathologic Processes
Demyelinating Autoimmune Diseases, CNS
Autoimmune Diseases of the Nervous System
Nervous System Diseases
Demyelinating Diseases
Autoimmune Diseases
Immune System Diseases
Natalizumab
Fingolimod Hydrochloride
Immunologic Factors
Physiological Effects of Drugs
Immunosuppressive Agents